Pernix Therapeutics to Acquire U.S Rights to Treximet and Summer Infant Beats on Revenues and Gets Upgrade from Roth Capital
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) shares hit a one year high after the company announced it would acquire the U.S rights to Treximet in an agreement with GlaxoSmithKline. Treximet is used for the acute treatment of migraine attacks with or without aura in adults. The company expects the acquisition to close no later than Aug. 1st. Pernix also revealed that it anticipates pro forma total revenue for the full year 2015 to exceed $230 million and sees EBTIDA margin greater than 40%.
Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells branded and generic pharmaceutical products. In addition, the company offers various generic pharmaceutical products in the areas of nutritional supplements, analgesics, urinary tract, women's health, pre-natal vitamins, and dental health, as well as allergy, respiratory, iron deficiency, nephrology, and pain management. It serves drug wholesalers, retail drug stores, mass merchandisers, and grocery store pharmacies in the United States.
Get more information on Pernix Therapeutics Holdings, Inc. and free access to the in depth equity report at: www.TrendingWallStreet.com/stockquote/PTX
TrendingWallStreet.com wants to help everyday people gain awareness about some of the hottest penny stocks trading in the stock market today. TrendingWallStreet.com releases momentum alerts on companies that you may have never heard about or thought about looking at. Take a few minutes to register with us at http://www.trendingwallstreet.com/ to get full access to our free stock reports.
Summer Infant, Inc. (NASDAQ: SUMR) beat analysts' estimates for earnings and revenue in Q1. For the first quarter, the company posted earnings of 5 cents a share, beating the Capital IQ Consensus Estimate of a loss of -1 cent a share by 6 cents. Summer Infant also posted revenue of $50.81 million for the quarter, while analysts expected revenue of $45.22 million. The stock was upgraded from "neutral" to "buy" by Roth Capital.
Summer Infant, Inc., through its subsidiaries, operates as a designer, marketer, and distributor of branded juvenile health, safety, and wellness products in North America and the United Kingdom. The company markets its products in various product categories, such as monitoring, safety, nursery, baby gear, feeding products, and furniture under the brand names of Summer and Born Free. It also offers various products under licenses with Carter's, Disney, and Garanimals.
Get more information on Summer Infant, Inc. and free access to the in depth equity report at: www.TrendingWallStreet.com/stockquote/SUMR
Disclosure: TrendingWallStreet.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.
Tags: